Anzeige
Mehr »
Login
Donnerstag, 25.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0B7QK | ISIN: GB0034330679 | Ticker-Symbol: DWV
Frankfurt
25.04.24
21:50 Uhr
0,156 Euro
-0,016
-9,30 %
Branche
Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
ANGLE PLC Chart 1 Jahr
5-Tage-Chart
ANGLE PLC 5-Tage-Chart
RealtimeGeldBriefZeit
0,1570,17323:00

Aktuelle News zur ANGLE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiSmallCap Risers and Fallers: Filtronic, Angle, Aptamer1
MiAngle inks deal with AstraZeneca3
MiAngle shares jump on supplier agreement with with AstraZeneca4
MiAngle agrees deal with Astrazeneca for tech to kill cancer cells4
MiANGLE Reaches Deal With AstraZeneca To Advance DDR Assay For Circulating Tumor Cell Detection207LONDON (dpa-AFX) - ANGLE plc (AGL.L, ANPCY) said that it has reached an agreement with AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE's existing DNA damage response...
► Artikel lesen
MiLiquid biopsy firm Angle signs new commercial agreement with AstraZeneca4
MiAngle PLC Announces New Commercial Agreement with AstraZeneca137ANGLE signs agreement to tailor existing Parsortix-based DNA damage response assay for use in pharmaceutical R&D GUILDFORD, SURREY / ACCESSWIRE / April 24, 2024 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a...
► Artikel lesen
MoIN BRIEF: Angle granted patents in US and Europe for Cellkeep slide1
MoAngle granted European patent for CellKeep, US patent imminent1
MoAngle PLC Announces US and EU Patents for Innovative CellKeep Slide111Proprietary cell recovery device and method eliminates over 70% of CTC cell loss from standard microscopy techniques increasing assay sensitivity GUILDFORD, SURREY / ACCESSWIRE / April 22, 2024 / ANGLE...
► Artikel lesen
08.04.Angle PLC Announces Parsortix HER2 Assay Showcased at AACR 2024321PARSORTIX HER2 ASSAY SHOWCASED AT PRESTIGIOUS INTERNATIONAL CANCER CONFERENCECTC HER2 assay being developed for HER2 targeted drugs and antibody drug conjugates presented at internationally renowned...
► Artikel lesen
22.03.Angle PLC Announces Parsortix at European Breast Cancer Conference265PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT A LEADING EUROPEAN BREAST CANCER CONFERENCEANGLE presenting two posters highlighting the utility of the Company's new Portrait+ CTC Staining Kit and Portrait...
► Artikel lesen
22.01.IN BRIEF: Angle highlights supportive data for DNA analysis tool1
22.01.Angle PLC Announces Potential Utility in Precision Oncology277REVIEW PAPER ON MOLECULAR ANALYSIS OF PARSORTIX CTC HARVEST HIGHLIGHTS POTENTIAL UTILITY IN PRECISION ONCOLOGYPaper published in the journal "Current Issues in Molecular Biology" special issue: advanced...
► Artikel lesen
10.01.Angle PLC Announces Standard Form for Notification of Major Holdings300GUILDFORD, SURREY / ACCESSWIRE / January 10, 2024 / ANGLE plc:TR-1: Standard form for notification of major holdings:NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA...
► Artikel lesen
04.01.Angle shares soar following "breakthrough" cancer diagnostics results2
04.01.AIM WINNERS & LOSERS: Angle soars on clinical tests; Likewise sales up2
04.01.Angle receives 'breakthrough results' from DNA molecular analysis3
04.01.Angle PLC Announces Breakthrough Clinical Results236BREAKTHROUGH CLINICAL RESULTS PROVIDE A UNIQUE INSIGHT INTO THE PROGRESSION OF EACH PATIENT'S CANCERCombined DNA Next Generation Sequencing of CTCs and ctDNA from the same blood sample highlights potential...
► Artikel lesen
02.01.Angle locks in $250,000 contract with Eisai4
Seite:  Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1